A large cluster-randomized trial in Kwale, Kenya, demonstrated that monthly mass administration of ivermectin reduced malaria infections by 26% in children aged 5–15. Published in The New England Journal of Medicine, the BOHEMIA trial offers robust evidence supporting ivermectin's complementary use alongside bed nets amidst challenges posed by insecticide resistance and behavioral adaptations of mosquitoes. This finding reinforces ivermectin’s public health role in vector control strategies to curb malaria transmission in high-burden regions.